GCGR and metabolic dysfunction-associated steatohepatitis: Another two GLP1R/GCGR dual agonists, Pemvidutide [152] and Survodutide [153], are under evaluation for NAFLD/NASH in phase I and II trials, respectively (NCT05006885 and NCT04771273).